GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: fluticasone propionate/salmeterol combination DISKUS

Study type: Interventional

Funder types: Industry

Identifiers

NCT00269087

SCO100648

Details and patient eligibility

About

This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

Enrollment: 122 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of COPD.

Exclusion criteria

• Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD.
• Other inclusion and exclusion criteria will be evaluated at the first study visit.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)